OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for diabetes complications associated with inflammation and fibrosis.
At OccuRx we are dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure. The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
OccuRx was established in 2014 with venture funding from Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund/MRCF), Brandon Capital Partners and Uniseed.
